Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up (original) (raw)

Abstract

Rationale

Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state–trait anger expression inventory (STAXI).

Objectives, materials, and methods

To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazole daily, n = 26, 21 female and 5 male patients; previous placebo group, n = 26, 22 female and 4 male patients).

Results

According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months.

Conclusion

Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.

Access this article

Log in via an institution

Subscribe and save

• Starting from 10 chapters or articles per month
• Access and download chapters and articles from more than 300k books and 2,500 journals
• Cancel anytime View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

• Briley M, Moret C (1993) Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 16:387–400
  Article PubMed CAS Google Scholar
• Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66:49–51
  Article PubMed CAS Google Scholar
• Franke GH (2002) SCL-90-R: Symptom-Checkliste von L.R. Derogatis. Goettingen, Beltz
  Google Scholar
• Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
  PubMed CAS Google Scholar
• Hamilton M (1976) Development of a rating scale; for primary depressive illness. Br J Soc Clin Psychol 6:278–296
  Google Scholar
• Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology 182:220–231
  Article PubMed CAS Google Scholar
• Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325–337
  Article PubMed CAS Google Scholar
• Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651–1658
  Article PubMed Google Scholar
• Jagadheesan K, Muirhead D (2004) Aripiprazole for acute mania. Am J Psychiatry 161:1926–1927
  Article PubMed Google Scholar
• Mobascher A, Mobascher J, Schlemper V, Winterer G, Malevani J (2006) Aripiprazole pharmacotherapy of borderline personality disorder. Phaarmacopsychiatry 39:111–112
  Article CAS Google Scholar
• Nickel M, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, C Egger, Anvar J, Rother W, Loew T, Kaplan P (2006) Aripiprazole in treatment of borderline patients: a double-blind, placebo-controlled study. Am J Psychiatry 163:833–838
  Article PubMed Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E. Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690
  Article PubMed CAS Google Scholar
• Schwenkmezger, P, Hodapp, V, Spielberger, CD (1992) The State-Trait Anger Expression Inventory. Goettingen, Bern
  Google Scholar
• Stevens J (1992) Applied multivariate statistics for the social sciences. Erlbaum, New Jersey
  Google Scholar
• Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J (2003) Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Personal Disord 17:233–242
  Article PubMed Google Scholar

Download references

Acknowledgment

We are grateful to Ann Marie Ackermann, JD, for translating and editing this article. The study was not funded.

Author information

Authors and Affiliations

1. Clinic for Psychosomatic Medicine and Psychotherapy, Medical University of Graz, 8990, Bad Aussee, Austria
   Marius K. Nickel
2. University Clinic for Psychiatry 1, PMU, Salzburg, Austria
   Marius K. Nickel
3. Department of Psychosomatic Medicine, University Clinic, Regensburg, Germany
   Thomas H. Loew
4. Psychosomatic Outpatient Clinic, University Medicine Clinic, LMU, Munich, Germany
   Francisco Pedrosa Gil

Authors

1. Marius K. Nickel
2. Thomas H. Loew
3. Francisco Pedrosa Gil

Corresponding author

Correspondence toMarius K. Nickel.

Rights and permissions

About this article

Cite this article

Nickel, M.K., Loew, T.H. & Gil, F.P. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up.Psychopharmacology 191, 1023–1026 (2007). https://doi.org/10.1007/s00213-007-0740-0

Download citation

• Received: 16 December 2006
• Accepted: 05 February 2007
• Published: 23 February 2007
• Issue date: May 2007
• DOI: https://doi.org/10.1007/s00213-007-0740-0

Keywords